|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
Rebecca Lee, the representitive | CHEN, ZHI-FANG | LIN, KUO-WEI | 037-580100 | No.29,Kejhong Road,Chu-Nan Site,Hsinchu Science Park,Miao-Li County,Taiwan 350,R.O.C. | 2015/09/08 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | Our company mainly focuses on producing APIs of Carbapenem antibiotics or accepting the development and manufacture of new drugs in the same class of antibiotics and owns plants and production lines exclusive to APIs of highly sensitizing antibiotics. Both of our headquarters in Chu-nan Science Park and branch in Tai-nan Science Park equip with plants and manufacturing facilities in compliance with cGMP standard of advanced nations and have successfully passed the inspection of DOH. Our company possesses several unique competitive advantages including excellent products, processes, techniques, business opportunities, and outstanding production lines in compliance with regulations. The perspective of our company is to become a worldwide leader in Carbapenem APIs based on experienced professionals, prominent techniques, and highly enthusiasm in service. |
Market Information ( 2023/10/04 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
518.984 | 17.35 | 17.20 | 17.35 | -0.05 | 256 | 9,129 | 4 | ||||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2023/10/05) |
TPEx measures adopted (2023/10/05) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | Y | Y | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
![]() |
![]() |
![]() |